e-learning
resources
Vienna 2012
Sunday, 02.09.2012
Airway diseases: from invasive to noninvasive biomarkers
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Characterisation of patients with difficult-to-treat and treatment-resistant severe asthma
F. Novelli, F.L. Dente, M.L. Bartoli, S. Cianchetti, A. Di Franco, L. Melosini, E. Bacci, P. Paggiaro (Italy)
Source:
Annual Congress 2012 - Airway diseases: from invasive to noninvasive biomarkers
Session:
Airway diseases: from invasive to noninvasive biomarkers
Session type:
Poster Discussion
Number:
299
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Novelli, F.L. Dente, M.L. Bartoli, S. Cianchetti, A. Di Franco, L. Melosini, E. Bacci, P. Paggiaro (Italy). Characterisation of patients with difficult-to-treat and treatment-resistant severe asthma. Eur Respir J 2012; 40: Suppl. 56, 299
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
Management of severe and difficult-to-treat asthma
Source: Annual Congress 2013 –Severe asthma: moving from phenotyping to endotyping
Year: 2013
Evaluation of the difficult-to-treat severe asthma patient in the clinic
Source: Eur Respir Mon 2011; 51: 16-27
Year: 2011
Management of difficult-to-treat severe asthma
Source: Eur Respir Mon 2011; 51: 282-296
Year: 2011
Characterisation of severe, steroid-dependent asthma patients who initiate biologics versus those who do not
Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments
Year: 2021
Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond
Source: Eur Respir J 2006; 28: Suppl. 50, 440s
Year: 2006
Severe therapy-resistant asthma
Source: International Congress 2016 – PG8 Paediatric asthma
Year: 2016
Evolution of patients with severe asthma treated with mepolizumab
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Efficacy of ruzam in the treatment of patients with mild-to-moderate asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 131s
Year: 2004
Evaluating the efficacy of omalizumab in severe persistent asthma patients
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Predictors of severe exacerbations in patients with moderate and severe asthma
Source: International Congress 2018 – Determinants and monitoring of asthma control
Year: 2018
Effect of ABPA treatment in severe asthma patients with acute and relapsed disease
Source: Virtual Congress 2020 – Advances in asthma treatment
Year: 2020
The use of omalizumab in the management of severe chronic paediatric asthma
Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Year: 2008
Characterization of patients with severe COPD
Source: International Congress 2018 – COPD around the world
Year: 2018
Impact of omalizumab in patients with severe asthma
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009
Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Distribution of biomarkers in severe asthma and severe uncontrolled asthma
Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research
Year: 2021
Combination asthma medication and healthcare use in severe or difficult-to-treat asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 131s
Year: 2004
Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations
Source: Eur Respir J, 53 (4) 1900147; 10.1183/13993003.00147-2019
Year: 2019
Diagnosing, treating and preventing severe asthma
Source: International Congress 2017 – State of the art session: "Airway diseases"
Year: 2017
Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept